Realtime | Geld | Brief | Zeit |
---|---|---|---|
0,126 | 0,147 | 21:01 | |
0,126 | 0,147 | 19:48 |
Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.01. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 4 | HKEx | ||
10.01. | BRII-B (02137): SUPPLEMENTAL ANNOUNCEMENT DISCLOSEABLE TRANSACTION IN RELATION TO NOMINEE DESIGNATION AGREEMENT | 1 | HKEx | ||
10.01. | BRII-B (02137): CHANGE OF ADDRESS OF PRINCIPAL PLACE OF BUSINESS IN HONG KONG | 1 | HKEx | ||
07.01. | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 2 | HKEx | ||
02.01. | Brii Biosciences acquires BRII-179 assets from VBI Vaccines | 3 | Pharmaceutical Business Review | ||
BRII BIOSCIENCES Aktie jetzt für 0€ handeln | |||||
31.12.24 | Brii Biosciences Limited: Brii Bio Announces Signing of Asset Purchase Agreements Acquiring BRII-179 IP Rights and Completed Patient Enrollment for ENRICH Study | 47 | PR Newswire | Further secures Brii's rights in BRII-179 with full control of intellectual property, future manufacturing and supply
Several combination treatment studies containing... ► Artikel lesen | |
31.12.24 | BRII-B (02137): DISCLOSEABLE TRANSACTION IN RELATION TO NOMINEE DESIGNATION AGREEMENT | - | HKEx | ||
20.12.24 | BRII-B (02137): INSIDE INFORMATION IN RELATION TO SHARE BUY-BACK PROGRAMME | - | HKEx | ||
19.11.24 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 2 | HKEx | ||
25.10.24 | BRII-B (02137): CANCELLATION OF SHARE OPTIONS AND RESTRICTED SHARE UNITS AND GRANT OF SHARE OPTIONS AND RESTRICTED SHARE UNITS | 1 | HKEx | ||
19.09.24 | BRII-B (02137): NOTIFICATION LETTER AND REQUEST FORM FOR NON-REGISTERED SHAREHOLDERS | - | HKEx | ||
19.09.24 | BRII-B (02137): NOTIFICATION LETTER AND CHANGE REQUEST FORM FOR REGISTERED SHAREHOLDERS | - | HKEx | ||
19.09.24 | BRII-B (02137): 2024 INTERIM REPORT | - | HKEx | ||
17.09.24 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
28.08.24 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN (REVISED) | 1 | HKEx | ||
27.08.24 | BRII-B (02137): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
19.08.24 | BRII-B (02137): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024 | 1 | HKEx | ||
05.08.24 | BRII-B (02137): DATE OF BOARD MEETING | - | HKEx | ||
31.07.24 | BRII-B (02137): VOLUNTARY ANNOUNCEMENT BUSINESS UPDATE | 1 | HKEx | ||
07.06.24 | Brii Biosciences Limited: Brii Bio Presents New Data from Its Ongoing Phase 2 Chronic Hepatitis B Trials at EASL Congress 2024 | 421 | PR Newswire | New translational data demonstrate that BRII-179-induced immune responses are associated with high HBsAg reduction in a subset of participants with chronic HBV infection
BRII-179 as add-on therapy... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIOGEN | 138,70 | +0,58 % | Biogen Says FDA And EMA Accept Applications For Higher Dose Regimen Of Nusinersen In SMA | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Thursday that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) and the European... ► Artikel lesen | |
ILLUMINA | 129,20 | -0,11 % | Inside the New Illumina MiSeq i100 Series: The Making of the Software | What's it like to build the software in a brand-new sequencer? Illumina's Aneesh Natarajan takes us on the journeyOriginally published on Illumina News Center NORTHAMPTON, MA / ACCESS Newswire / January... ► Artikel lesen | |
NANOREPRO | 1,395 | -0,36 % | Nanorepro: "Bedeutender Schritt für die Zukunft" | Nanorepro kommt 2024 auf einen Umsatz von 4,4 Millionen Euro (Vorjahr: 3,2 Millionen Euro). Mit Corona-Tests, dem Umsatztreiber in früheren Jahren, werden dabei nur noch marginale Umsätze erzielt. Vor... ► Artikel lesen | |
BRAIN BIOTECH | 3,100 | -0,32 % | EQS-DD: BRAIN Biotech AG: Adriaan Moelker, Kauf | Meldung und öffentliche Bekanntgabe der Geschäfte von Personen, die Führungsaufgaben wahrnehmen, sowie in enger Beziehung zu ihnen stehenden Personen
16.01.2025 / 11:25... ► Artikel lesen | |
BIONXT SOLUTIONS | 0,280 | +3,70 % | Bayer wachgeküsst! BioNxt Solutions, Novo Nordisk - jetzt in die Gewinner von morgen investieren | Die Wirtschaft befindet sich im Wandel, denn mit der rasanten Entwicklung im Bereich Künstliche Intelligenz können technologische Innovationen entwickelt werden, die neue Maßstäbe setzen könnten. Diese... ► Artikel lesen | |
INFLARX | 2,202 | -4,26 % | InflaRx: Spannende Phase | Vor wenigen Jahren wäre der Aktienkurs von InflaRx bei so einer Meldung vermutlich durch die Decke gegangen. Immerhin hat das Biotechunternehmen aus Jena mit Listing an der Nasdaq die EU-weite Zulassung... ► Artikel lesen | |
SIRONA BIOCHEM | 0,036 | -2,74 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
TREVENA | 0,153 | 0,00 % | Trevena Inc.: Trevena Reports Third Quarter 2024 Results and Provides Business Update | CHESTERBROOK, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,574 | +9,13 % | Defence Therapeutics Inc.: Defence to Connect with Industry Leaders and Potential Partners During the JP Morgan Healthcare Conference in San Francisco. Plans to Expand the Next Generation of Radio-Immuno Conjugates in 2025 | Montreal, Quebec--(Newsfile Corp. - January 10, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company") a Canadian biopharmaceutical company developing radiopharmaceuticals... ► Artikel lesen | |
BURCON NUTRASCIENCE | 0,056 | -10,00 % | Burcon NutraScience Corporation: Burcon Launches Groundbreaking Sunflower Protein Isolate | Vancouver, British Columbia--(Newsfile Corp. - January 8, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
CYTODYN | 0,208 | 0,00 % | CytoDyn Inc.: December 2024 Letter to Shareholders | VANCOUVER, Washington, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Dear Shareholders, As I look back on 2024, during which CytoDyn Inc. ("CytoDyn" or the "Company") achieved multiple crucial milestones... ► Artikel lesen | |
TME PHARMA | 0,068 | -0,15 % | TME Pharma N.V.: TME Pharma: Half-yearly Report on the Liquidity Contract With Invest Securities | Regulatory News:
TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment... ► Artikel lesen | |
IMMUNIC | 0,980 | +3,10 % | IMUX-Aktie erreicht 52-Wochen-Tief bei 0,97 US-Dollar | ||
PHIO PHARMACEUTICALS | 2,250 | -3,85 % | Phio Pharmaceuticals Corp.: Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series | Marlborough, Massachusetts--(Newsfile Corp. - January 22, 2025) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA... ► Artikel lesen | |
IOVANCE BIOTHERAPEUTICS | 5,928 | -0,34 % | Iovance Biotherapeutics, Inc.: Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) |